Data for validation and adjustment of APACHE II score in cardiogenic shock patients treated with a percutaneous left ventricular assist device

Johannes Mierke; Thomas Nowack; Tobias Loehn; Franziska Kluge; Frederike Poege; Felix Woitek; Norman Mangner; Karim Ibrahim; Axel Linke; Christian Pfluecke

doi:10.1016/j.dib.2022.108199

Data for validation and adjustment of APACHE II score in cardiogenic shock patients treated with a percutaneous left ventricular assist device

Data Brief. 2022 Apr 22:42:108199. doi: 10.1016/j.dib.2022.108199. eCollection 2022 Jun.

Authors

Affiliations

¹ Technische Universität Dresden, Department of Internal Medicine and Cardiology, Herzzentrum Dresden, University Clinic, Dresden, Germany.
² Kreiskrankenhaus Freiberg, Klinik für Innere Medizin II, Freiberg, Germany.
³ Klinikum Chemnitz, Klinik für Innere Medizin I, Chemnitz, Germany.

Abstract

A precise prognosis is of imminent importance in intensive care medicine. This article provides data showing the overestimation of intrahospital mortality by APACHE II score in various subgroups of cardiogenic shock patients treated with a percutaneous left ventricular assist device. The data set includes additional baseline characteristics regarding age, pre-existing diseases, characteristics of coronary artery disease, characteristics of cardiopulmonary resuscitation, and hemodynamic parameter not included in the APACHE II score. Further data were provided which characterize derivation and validation group. Both groups were used for adjustment of the APACHE II approach. The data are supplemental to our original research article titled "Predictive value of the APACHE II score in cardiogenic shock patients treated with a percutaneous left ventricular assist device" (Mierke et al., IJC Heart & Vasculature. 40 (2022) 101013. https://doi.org/10.1016/j.ijcha.2022.101013).

Keywords: Acute Physiology and Chronic Health Evaluation II score; Impella CP®; Mechanical circulatory support.; Percutaneous left ventricular assist device; Predicted mortality.